Xyall BV, a leading MedTech innovator in molecular pathology, has launched its Tissector High Throughput (HT) system for greater diagnostic precision. The Netherlands-based company says this is a world first – enabling high volume, molecular diagnostic laboratories to capitalize commercially on the company’s unique, automated, tissue dissection technology.

Xyall‘s Tissector HT solution uses state-of-the-art technology, image registration, robotics and workflow optimization. It is designed for continuous operation and is fully integrated with digital pathology solutions and the laboratory workflow system (LIMS). The Tissector HT can hold 1,800 slides, dissect a minimum of 80 dissection slides per hour with an accuracy of < 0.1 mm and is designed for three hours unattended operation. The system is easy to use, combining high throughput with the highest accuracy.

Tissue dissection, even in large-scale commercial labs, remains a manual, labour-intensive process at risk of error and cross contamination. “The Xyall solution provides the missing link for customers,” explained Guido Du Pree, Xyall’s CEO.

Current practice involves manually pen-marking Regions of Interest (ROIs) on Hematoxylin & Eosin (H&E) stained slides. Using visual assessment, lab technicians then translate these ROIs into dissection slides, manually scraping the tissue and placing it in small containers.

Order-to-built systems

“Xyall has already won contracts for order-to-built systems from two of the largest laboratories in the US, with high levels of interest from other molecular diagnostic laboratories requiring industrial-sized platforms,” said Du Pree.

“With new therapies coming to the market, and transformative technologies in PCR and next generation sequencing, precision medicine is being revolutionized – providing physicians and patients with the highest quality information about their health.

“However, tissue dissection to enable molecular profiling is still a labour intense, subjective process. Our pioneering technology transforms how this is done – delivering greater accuracy, consistency and overall improved quality control.”

Table-top version for hospital-based labs

Alongside the new large-scale, industrial system, Xyall is developing a smaller, table-top version for hospital-based molecular pathology laboratories. Based on the same technology, the company expects to have this second system commercially available in Q1 2022.

Du Pree added: “Worldwide shortages of experienced pathology staff are already putting labs under pressure. The Xyall solution will address this, helping customers to make more efficient use of existing, and increasingly scarce, staffing levels.”

• For more information, visit: Xyall.com

LifeSignals has received FDA Class II 510 (k) approval for the LifeSignals LX1550 Multiparameter Remote Monitoring Platform. This follows recent CE marking for the wireless platform for continuous collection of patient physiological data.

Innovative Health Sciences has received ISO 13485 quality management system and CE Mark certification for the Insignis Syringe Infusion System.